Login / Signup

Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions.

Julio C ChavezFarah YassineJose Sandoval-SusMohamed A Kharfan-Dabaja
Published in: International journal of hematologic oncology (2021)
Anti-CD19 CAR T-cell therapy is a viable option for poor risk refractory B-cell NHLs.
Keyphrases
  • cell therapy
  • stem cells
  • mesenchymal stem cells
  • nk cells